Royalty Pharma plc Interest Income, Other
Royalty Pharma plc (RPRX) reported Interest Income, Other of $5.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-08-05
- Royalty Pharma plc interest income, other for the quarter ending 2026-06-30 was $5.13M, a 38.43% decline year-over-year.
- Royalty Pharma plc interest income, other for the quarter ending 2026-03-31 was $6.23M, a 44.83% decline year-over-year.
- Royalty Pharma plc interest income, other for the quarter ending 2025-12-31 was $7.07M, a 21.76% decline year-over-year.
- Royalty Pharma plc interest income, other for the quarter ending 2025-09-30 was $6.90M, a 60.57% decline year-over-year.
- Royalty Pharma plc interest income, other for fiscal 2025 was $33.59M, a 29.05% decline from fiscal 2024.
- Royalty Pharma plc interest income, other for fiscal 2024 was $47.34M, a 34.51% decline from fiscal 2023.
- Royalty Pharma plc interest income, other for fiscal 2023 was $72.29M, a 7.72% decline from fiscal 2022.
- Royalty Pharma plc interest income, other for fiscal 2022 was $78.33M.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.13M 10-Q · filed 2026-08-05 | $11.36M 10-Q · filed 2026-08-05 | $18.43M derived: sum of 3 quarters · filed 2026-08-05 | $25.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $6.23M 10-Q · filed 2026-05-06 | $13.30M derived: sum of 2 quarters · filed 2026-05-06 | $20.20M derived: sum of 3 quarters · filed 2026-05-06 | $28.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $7.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $13.97M derived: sum of 2 quarters · filed 2026-02-11 | $22.30M derived: sum of 3 quarters · filed 2026-08-05 | $33.59M 10-K · filed 2026-02-11 |
| 2025-09-30 | $6.90M 10-Q · filed 2025-11-05 | $15.23M derived: sum of 2 quarters · filed 2026-08-05 | $26.52M 10-Q · filed 2025-11-05 | $35.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $8.33M 10-Q · filed 2026-08-05 | $19.62M 10-Q · filed 2026-08-05 | $28.65M derived: sum of 3 quarters · filed 2026-08-05 | $46.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $11.29M 10-Q · filed 2026-05-06 | $20.33M derived: sum of 2 quarters · filed 2026-05-06 | $37.84M derived: sum of 3 quarters · filed 2026-05-06 | $51.22M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $9.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $26.55M derived: sum of 2 quarters · filed 2026-02-11 | $39.93M derived: sum of 3 quarters · filed 2026-02-11 | $47.34M 10-K · filed 2026-02-11 |
| 2024-09-30 | $17.51M 10-Q · filed 2025-11-05 | $30.89M derived: sum of 2 quarters · filed 2025-11-05 | $38.31M 10-Q · filed 2025-11-05 | $44.81M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $13.38M 10-Q · filed 2025-08-06 | $20.80M 10-Q · filed 2025-08-06 | $27.30M derived: sum of 3 quarters · filed 2026-02-11 | $50.73M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $7.42M 10-Q · filed 2025-05-08 | $13.92M derived: sum of 2 quarters · filed 2026-02-11 | $37.35M derived: sum of 3 quarters · filed 2026-02-11 | $63.01M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $29.94M derived: sum of 2 quarters · filed 2026-02-11 | $55.59M derived: sum of 3 quarters · filed 2026-02-11 | $72.29M 10-K · filed 2026-02-11 |
| 2023-09-30 | $23.44M 10-Q · filed 2024-11-06 | $49.09M derived: sum of 2 quarters · filed 2024-11-06 | $65.79M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $25.65M 10-Q · filed 2024-08-08 | $42.35M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $16.70M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $78.33M 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |